Daniel C. Chambers
Has grant
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Recent Grants
Grant: Close
The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients
Open Date: 2021-01-01
Close Date: 2024-01-01
Grant: Close
Silicosis - Harnessing new ideas to conquer the re-emergence of an ancient lung disease - The SHIELD Study
Open Date: 2021-01-01
Close Date: 2024-01-01
Grant: Close
The TELO-SCOPE study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis? (2020–2025)
Open Date: 2020-01-01
Close Date: 2025-01-01
Grant: Close
Silicosis – Harnessing new Ideas to conquer the re-Emergence of an ancient Lung Disease -The SHIELD Study
Open Date: 2019-01-01
Close Date: 2019-01-01
Grant: Close
Ambulatory oxygen for interstitial lung disease
Open Date: 2018-01-01
Close Date: 2022-01-01
Articles (10)
Year:
2023
Year:
2022
Background and Objective Identification of an exposure is integral to the diagnosis, management, and prognostication of chronic hypersensitivity pneumonitis (CHP). Standardized questionnaires may aid in the identification of exposures, however, there currently are no evidence‐based patient‐validated questionnaires available. Key qualifiers (including duration and frequency) which indicate exposure relevance are also poorly defined. This study assessed the use of a standardized CHP exposure questionnaire in the identification of exposures and diagnostic confidence of CHP. Methods People with a multi‐disciplinary meeting (MDM) diagnosis from five Australian interstitial lung disease (ILD) expert centres who provided informed consent were included. Participants completed a previously developed standardized CHP Exposure Questionnaire. Responses were collected with the participant's MDM data, including diagnosis, diagnostic confidence, and clinician‐elicited exposures. Results One hundred thirty participants (IPF = 58, CHP = 24, CTD‐ILD = 17, unclassifiable = 19, other = 12) were included. In 33% of CHP participants, a standardized questionnaire elicited an exposure where the clinician did not. 63% of these had provisional low confidence CHP; and an exposure history would have increased the diagnostic confidence in these cases. Using the standardized questionnaire, 96% of CHP participants reporting any exposure, compared with 75% of non‐HP ILD participants. CHP participants were 3.5 times more likely ( p = 0.004) to report their symptoms improved on avoidance, and 2.3 times more likely ( p = 0.018) to report daily frequent exposure, compared with non‐HP ILDs. Conclusion A standardized questionnaire which elicits exposure characteristics in addition to presence or absence of relevant exposures can increase the diagnostic confidence of CHP and reduce the proportion of antigen‐indeterminate CHP.
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (6)
Magnus Ekström
-
Michael Harhay
Assistant Professor
University of Pennsylvania
Adam Frankel
University of Queensland
Ian Glaspole
-
John Mackintosh
-
Dusan Ilic
University of Newcastle Australia
Make your next move.
Prepare your application
Review drafts before you send them.